Alpaca nanobodies show promising results in CAR-T solid tumor treatment

Scientists from Boston Children’s Hospital and Massachusetts Institute of Technology (MIT) have used alpaca-derived nanobodies to create a novel approach to CAR T cell therapy that addresses the challenge of treating patients with solid tumor cancers. Currently, CAR-T cell immunotherapy has been applied to the treatment of non-solid tumors such as acute lymphoblastic leukemia (ALL).

The Importance of Standards and Manufacturing Needs – Recent Meetings

On Monday, March 18, the Standards Coordinating Body convened for a workshop on standards. The group discussed how standards are critical for the transfer of novel technologies from academia to clinical use. The FDA’s Judy Arcidiacono, one of the keynote speakers, discussed how standards are imperative to building the foundation of regenerative medicine innovation. The

New Review Article Outlines Mechanisms of Resistance to CAR T Cell Therapy

Following successful clinical studies, the FDA and regulatory authorities around the world have approved the use of axicabtagene ciloleucel (Yescarta™) for patients with large-B-cell lymphomas and tisagenlecleucel (Kymriah™) for adults with certain types of non-Hodgkin lymphoma. Despite its success as a novel way of treating cancer, physician scientists are realizing that 30%-50% of patients who

The Akron Team Participates in the 4th Annual Innate Killer Summit

The Akron team recently attended the 4th Innate Killer Summit, held in in San Diego, California. The conference provided an excellent opportunity to participate in presentations and workshops covering cutting-edge research, recent clinical data, and commercial developments in the growing NK cell therapy market. More than 250 attendees collaborated and shared knowledge on ways we

New methods to improve cryopreservation for immunotherapies using a bioinspired solution

The preservation of biological samples is critical to the success of experimental studies and clinical treatments in the emergent field of immunotherapy. Cryopreservation – keeping cells at sub-zero temperatures – slows metabolic activity significantly, enabling storage and transportation, as well as a return to functionality upon thaw. Of course, it’s not as simple as placing

Akron Participates in Newly Published Study Modelling Cost of Goods for Allogeneic CAR T

Cell and gene therapies have demonstrated excellent clinical results across a range of indications with chimeric antigen receptor (CAR)–T cell therapies among the first to reach market. Although these therapies are currently manufactured using patient-derived cells, therapies using healthy donor cells are in development, potentially offering avenues toward process improvement and patient access. An allogeneic

FDA-approved drug may prevent Cytokine Release Syndrome (CRS) associated with cell therapy

Recently published research findings suggest that we may be able to prevent Cytokine Release Syndrome (CRS) through the oral administration of an FDA-approved drug. CAR-T therapy is a promising new approach to cancer treatment. However, a devastating side effect of CAR-T cell infusion is CRS. The patient’s infused activated T cells release interferon gamma (IFN-γ)

A new 3D bio-printing method shows great potential for tissue engineering scaffolds

Electrospinning has been an attractive scaffold fabrication technique for over a decade capable of introducing micro-architectural ques to enhance tissue engineering modalities. Nonetheless, only a handful or architecturally relevant structures can be accomplished with this technique which require complex set-ups in order to be rendered properly. On the other hand, 3D Bio-Printing has emerged as